These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38024821)

  • 1. Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia.
    Davidson R; Medeiros M
    J Med Life; 2023 Aug; 16(8):1294-1296. PubMed ID: 38024821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
    Bannister ML; Thomas NL; Sikkel MB; Mukherjee S; Maxwell C; MacLeod KT; George CH; Williams AJ
    Circ Res; 2015 Apr; 116(8):1324-35. PubMed ID: 25648700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
    Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
    Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC
    Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.
    Liu N; Denegri M; Ruan Y; Avelino-Cruz JE; Perissi A; Negri S; Napolitano C; Coetzee WA; Boyden PA; Priori SG
    Circ Res; 2011 Jul; 109(3):291-5. PubMed ID: 21680895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moving in the right direction: elucidating the mechanisms of interaction between flecainide and the cardiac ryanodine receptor.
    Bannister ML; MacLeod KT; George CH
    Br J Pharmacol; 2022 Jun; 179(11):2558-2563. PubMed ID: 34698387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
    Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
    Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.
    Yang PC; Moreno JD; Miyake CY; Vaughn-Behrens SB; Jeng MT; Grandi E; Wehrens XH; Noskov SY; Clancy CE
    J Physiol; 2016 Feb; 594(3):567-93. PubMed ID: 26515697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia.
    Kohli U; Aziz Z; Beaser AD; Nayak HM
    Pacing Clin Electrophysiol; 2019 Aug; 42(8):1146-1154. PubMed ID: 30912151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flecainide in patient with aggressive catecholaminergic polymorphic ventricular tachycardia due to novel RYR2 mutation.
    Wangüemert-Pérez F; Ruiz-Hernández PM; Campuzano O; Caballero-Dorta E; Bosch C; Brugada J; Brugada R
    Minerva Cardioangiol; 2014 Aug; 62(4):363-6. PubMed ID: 25012103
    [No Abstract]   [Full Text] [Related]  

  • 11. Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.
    Wangüemert Pérez F; Hernández Afonso JS; Groba Marco MDV; Caballero Dorta E; Álvarez Acosta L; Campuzano Larrea O; Pérez G; Brugada Terradellas J; Brugada Terradellas R
    Rev Esp Cardiol (Engl Ed); 2018 Mar; 71(3):185-191. PubMed ID: 28789916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catecholaminergic Polymorphic Ventricular Tachycardia: A Review of Therapeutic Strategies.
    Bergeman AT; Wilde AAM; van der Werf C
    Card Electrophysiol Clin; 2023 Sep; 15(3):293-305. PubMed ID: 37558300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.
    Watanabe H; Chopra N; Laver D; Hwang HS; Davies SS; Roach DE; Duff HJ; Roden DM; Wilde AA; Knollmann BC
    Nat Med; 2009 Apr; 15(4):380-3. PubMed ID: 19330009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How does flecainide impact RyR2 channel function?
    Salvage SC; Huang CL; Fraser JA; Dulhunty AF
    J Gen Physiol; 2022 Sep; 154(9):. PubMed ID: 35713932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
    Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
    Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of antiarrhythmic effects of flecainide in catecholaminergic polymorphic ventricular tachycardia.
    Watanabe H; Steele DS; Knollmann BC
    Circ Res; 2011 Sep; 109(6):712-3. PubMed ID: 21885838
    [No Abstract]   [Full Text] [Related]  

  • 17. Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
    Nozaki Y; Kato Y; Uike K; Yamamura K; Kikuchi M; Yasuda M; Ohno S; Horie M; Murayama T; Kurebayashi N; Horigome H
    Circ J; 2020 Jan; 84(2):226-234. PubMed ID: 31875585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs.
    Li N; Wang Q; Sibrian-Vazquez M; Klipp RC; Reynolds JO; Word TA; Scott L; Salama G; Strongin RM; Abramson JJ; Wehrens XHT
    Int J Cardiol; 2017 Jan; 227():668-673. PubMed ID: 27838126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
    Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA
    Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.
    van der Werf C; Kannankeril PJ; Sacher F; Krahn AD; Viskin S; Leenhardt A; Shimizu W; Sumitomo N; Fish FA; Bhuiyan ZA; Willems AR; van der Veen MJ; Watanabe H; Laborderie J; Haïssaguerre M; Knollmann BC; Wilde AA
    J Am Coll Cardiol; 2011 May; 57(22):2244-54. PubMed ID: 21616285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.